JP Morgan Chase’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1
| Closed | -$4 | – | 7140 |
|
|
2025
Q1 | $4 | Hold |
1
| – | – | ﹤0.01% | 7233 |
|
|
2024
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 7345 |
|
|
2024
Q3 | $2 | Hold |
1
| – | – | ﹤0.01% | 7351 |
|
|
2024
Q2 | $2 | Hold |
1
| – | – | ﹤0.01% | 7275 |
|
|
2024
Q1 | $2 | Hold |
1
| – | – | ﹤0.01% | 7308 |
|
|
2023
Q4 | $2 | Sell |
1
-38
| -97% | -$83 | ﹤0.01% | 7470 |
|
|
2023
Q3 | $66 | Buy |
39
+38
| +3,800% | +$86 | ﹤0.01% | 6958 |
|
|
2023
Q2 | $2 | Hold |
1
| – | – | ﹤0.01% | 6851 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6747 |
|
|
2022
Q4 | $0 | Sell |
1
-1
| -50% | -$7 | ﹤0.01% | 6591 |
|
|
2022
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 6493 |
|
|
2022
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 6506 |
|
|
2022
Q1 | $0 | Sell |
2
-1,396
| -100% | -$30K | ﹤0.01% | 6630 |
|
|
2021
Q4 | $43K | Buy |
1,398
+1,396
| +69,800% | +$46.2K | ﹤0.01% | 6000 |
|
|
2021
Q3 | $0 | Sell |
2
-8,628
| -100% | -$255K | ﹤0.01% | 6505 |
|
|
2021
Q2 | $254K | Sell |
8,630
-2,530
| -23% | -$70.1K | ﹤0.01% | 5107 |
|
|
2021
Q1 | $350K | Sell |
11,160
-2,658
| -19% | -$89.1K | ﹤0.01% | 4885 |
|
|
2020
Q4 | $366K | Buy |
13,818
+10,830
| +362% | +$274K | ﹤0.01% | 4543 |
|
|
2020
Q3 | $83K | Sell |
2,988
-1,095
| -27% | -$26.3K | ﹤0.01% | 4778 |
|
|
2020
Q2 | $81K | Buy |
4,083
+3,300
| +421% | +$60.1K | ﹤0.01% | 4654 |
|
|
2020
Q1 | $12K | Sell |
783
-4,673
| -86% | -$82.7K | ﹤0.01% | 5027 |
|
|
2019
Q4 | $94K | Buy |
5,456
+4,654
| +580% | +$77.9K | ﹤0.01% | 4923 |
|
|
2019
Q3 | $20K | Buy |
802
+169
| +27% | +$4.64K | ﹤0.01% | 5409 |
|
|
2019
Q2 | $21K | Buy |
+633
| New | +$24.8K | ﹤0.01% | 5425 |
|
JP Morgan Chase's CKPT Position: Q2 2025 in Review
JP Morgan Chase sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 1 share — an estimated $4 sold.
JP Morgan Chase first reported a position in CKPT in Q2 2019 and held it in 24 quarters. The position peaked at $366K in Q4 2020. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- JP Morgan Chase reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 1 Checkpoint Therapeutics share in Q2 2025, an estimated $4.
- JP Morgan Chase first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 24 quarters.
- JP Morgan Chase's Checkpoint Therapeutics position peaked at $366K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.